The NTIS website and supporting ordering systems are undergoing a major upgrade from 8PM on September 25th through approximately October 6. During that time, much of the functionality, including subscription and product ordering, shipping, etc., will not be available. You may call NTIS at 1-800-553-6847 or (703) 605-6000 to place an order but you should expect delayed shipment. Please do NOT include credit card numbers in any email you might send NTIS.
Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website; (3) the federal government Internet portal; or (4) a web search conducted using a commercial search engine such as
Accession Number ADA567575
Title Characterizing and Targeting Replication Stress Response Defects in Breast Cancer.
Publication Date Aug 2012
Media Count 24p
Personal Author C. Lin E. Wang H. Dai J. Lee S. Lin
Abstract During the second year of this project, we have made significant progress in several of our proposed tasks. We found that both TUSC4 and PRMT5 may function as RSR genes through their activities in facilitating HR DNA repair. Both TUSC4 and PRMT5 inhibit cell proliferation and cellular transformation, and may function as potential tumor suppressor genes in breast cancer. DNA2 is also involved in HR repair in response to RSR. However, unlike TUSC4 or PRMT5, DNA2 may exert an oncogenic function in cancer cells. In addition, we identified and validated APP as an RSR-defect-specific membrane protein and have successfully conjugated APP antibody to hollow gold nanoparticles, an important step for developing nano-imaging and nano-targeting in the future. We also identified additional RSR-defect-specific membrane molecules by SILAC. We will seek to determine if any of these molecules may serve as a better marker than APP for detecting and targeting RSR-defect cells. Finally, using Prestwick chemical library, we have successfully completed our screen for drugs that may specifically target on RSR-defect cells. We will evaluate the sensitivity and specificity of these drugs on killing the RSR- defect cells soon.
Keywords Breast cancer
Deoxyribonucleic acids
Drug screening
Gene signature
Replication stress response

Source Agency Non Paid ADAS
NTIS Subject Category 57E - Clinical Medicine
57W - Stress Physiology
Corporate Author M.D. Anderson Cancer Center, Houston, TX.
Document Type Technical report
Title Note Annual rept. 15 Jul 2011-14 Jul 2012.
NTIS Issue Number 1309
Contract Number W81XWH-10-1-0558

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader